appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
News & Opinions
Ajooni Biotech Eyes Additional Rs 200 Crore Revenue from Commercial Production of Moringa by FY2025-26 - News18
6 months ago•News18
Ajooni Biotech Standalone June 2023 Net Sales at Rs 21.00 crore, up 70.61% Y-o-Y
1 year ago•Moneycontrol
Ajooni Biotech Ltd launches pilot project in Rajasthan for exploring potential in MORINGA farming
1 year ago•Free Press Journal
Ajooni Biotech rights issue to raise Rs 29 cr open on Wednesday
2 years ago•The Hindu Businessline
Ajooni Biotech Standalone September 2022 Net Sales at Rs 10.29 crore, down 44.04% Y-o-Y
2 years ago•Moneycontrol
Ajooni Biotech successfully develops Lumpy Skin Disease Medicine for Cattle
2 years ago•India Infoline
Ajooni Biotech reports standalone net loss of Rs 0.06 crore in the March 2022 quarter
2 years ago•Business Standard